查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087548

短腸症候群市場：2026-2032年全球市場預測（依治療方法、給藥途徑、病患年齡、病因和最終用途分類）

Short Bowel Syndrome Market by Treatment Type, Route Of Administration, Patient Age, Etiology, End Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，短腸症候群市場將成長至 23.1 億美元，複合年成長率為 9.50%。

主要市場統計數據
基準年 2025 12.2億美元
預計年份：2026年 13.2億美元
預測年份 2032 23.1億美元
複合年成長率 (%) 9.50%

短腸症候群（SBS）是大規模的腸道功能障礙，由廣泛的腸切除、先天性腸道缺陷或嚴重功能障礙導致的吸收不足引起。此疾病與腸外營養或靜脈輸液依賴、反覆脫水、電解質失衡、導管相關性血流感染、腎臟併發症以及與腸道功能障礙相關的肝臟疾病密切相關。

對於製藥和生物技術行業的相關人員，短腸症候群(SBS) 市場的特徵在於其罕見疾病的經濟性、特殊的處方模式以及可衡量的臨床終點，例如減少腸外營養攝入量、縮短液體攝入天數、改善水合作用和腸道適應。隨著 FDA 和 EMA 批准的特度格魯肽，GLP-2 類似物療法已成為合格的成人和兒童患者的有效治療方案。同時，新一代腸分泌、微生物組和再生醫學方法正在重塑 SBS 的長期治療策略。

SBS治療前景的變革性變化

嬰兒搖晃症候群 (SBS) 的治療正從終身營養支持轉向有針對性的腸道功能恢復。目前，多學科護理模式結合了飲食最佳化、口服補液策略、運動抑制療法、抑酸療法、微量營養素管理、家庭腸外營養、手術重組以及基於 GLP-2 的藥物治療，以減少對腸外營養的依賴。

人工智慧對新加坡科技廣播公司創新工作的累積影響

人工智慧（AI）在短腸症候群（SBS）的整個藥物發現和商業化過程中發揮著越來越重要的作用。 AI驅動的文獻挖掘、生物標記發現、數位表現型分析和臨床試驗可行性建模可以幫助識別高風險亞組，最佳化入組標準，並加快罕見疾病患者的招募，因為這些疾病的患者數量有限，治療也集中在專門的醫療機構。

全球 SBS 醫療保健領域的關鍵區域見解

北美仍然是短腸症候群（SBS）治療的主要地區，這得益於其完善的家庭腸外營養基礎設施、孤兒藥核准流程、專業的藥房網路、保險公司在罕見疾病治療方面的經驗以及腸道功能康復中心的高密度分佈。歐洲受益於跨境臨床專業知識、國家級腸道功能障礙應對服務以及歐洲藥品管理局（EMA）批准的SBS治療方案，但保險報銷時間、技術評估結果以及家庭腸外營養的可及性因國家而異。

關於SBS市場准入的關鍵群體特定見解

在歐盟內部，集中化的監管流程和國家衛生技術評估會影響GLP-2類似物和家庭腸外營養服務的引入，因此，針對特定國家的證據包對於市場准入至關重要。七國集團（G7）國家通常擁有完善的罕見疾病基礎設施、轉診途徑、居家照護服務和藥物安全監測系統，這為在臨床上顯著減少腸外營養支持的情況下，支持高品質的短腸症候群（SBS）治療奠定了基礎。

關鍵國家洞察：優先考慮SBS市場

美國在短腸症候群（SBS）的商業化方面處於領先地位，其手段包括對孤兒藥的優先待遇、設立專門的腸道功能障礙中心、建立家庭靜脈營養網路以及透過專科藥房進行分銷。加拿大強調實證報銷和省級准入途徑，而墨西哥和巴西則透過三級醫療機構、胃腸病轉診中心和私人醫療機構的專家來建構醫療服務體系。英國、德國、法國、義大利和西班牙在胃腸病學和臨床營養方面擁有雄厚的實力，但在報銷速度、區域預算、家庭腸外營養基礎設施和醫療技術評估要求等方面存在差異。

為SBS產業領導者提供的實用建議

產業領導者應優先考慮將短腸症候群（SBS）療法與減少靜脈營養攝取、縮短輸液時間、改善體液平衡、降低導管併發症風險、減輕住院負擔以及提高生活品質聯繫起來的證據。應透過註冊登記、長期隨訪研究、患者報告結局以及來自腸道功能障礙中心的真實世界數據來評估療效。

SBS市場分析的調查方法

本執行摘要是基於已發表的與短腸症候群、腸道功能障礙、腸外營養、GLP-2類似物療法、兒童和成人診療路徑以及區域醫療服務趨勢相關的臨床、監管和醫療服務證據的系統性回顧。資訊來源包括法規核准文件、臨床指引、同儕審查文獻、衛生技術評估原則、罕見病診療基礎設施指標。

結論：短腸症候群的戰略展望

短腸症候群正從一種僅需替代療法的疾病，轉變為以腸道復健為標靶的市場。臨床目標不再僅限於依靠腸外營養維持生存，而是日益涵蓋腸道適應、減少併發症、提高獨立生活能力、改善體液平衡以及永續的長期治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章短腸症候群市場：依治療類型分類

  • 營養支持
    • 腸外營養
    • 經腸營養
  • 藥物治療
    • GLP-2 類似物
    • 生長激素荷爾蒙療法
    • 麩醯胺酸療法
    • 抗生素
  • 手術治療
    • 腸道延長
    • 腸移植

第8章短腸症候群市場：依給藥途徑分類

  • 腸外
    • 靜脈
    • 皮下
  • 口服

第9章短腸症候群市場：依患者年齡分類

  • 成人
  • 老年人
  • 兒童

第10章短腸症候群市場：依病因分類

  • 創傷
  • 克隆氏症
  • 腸繫膜缺血
  • 放射性腸炎
  • 腫瘤切除

第11章短腸症候群市場：依最終用途分類

  • 居家護理設施
  • 醫院
  • 專科診所
  • 門診手術中心
  • 研究機構

第12章短腸症候群市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章短腸症候群市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章短腸症候群市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Ardelyx, Inc.
  • Emmaus Life Sciences, Inc.
  • Hanmi Pharmaceutical Co., Ltd.
  • Ironwood Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • NorthSea Therapeutics BV
  • Nutrinia Ltd.
  • OxThera AB
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals, Inc.
  • Sancilio & Company, Inc.
  • Takeda Pharmaceutical Company Limited
  • Theriva Biologics, Inc.
  • Zealand Pharma A/S
Product Code: MRR-0309FBC51139

The Short Bowel Syndrome Market is projected to grow by USD 2.31 billion at a CAGR of 9.50% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.22 billion
Estimated Year [2026] USD 1.32 billion
Forecast Year [2032] USD 2.31 billion
CAGR (%) 9.50%

Short bowel syndrome (SBS) is a rare, high-burden intestinal failure condition caused by inadequate absorptive capacity after major bowel resection, congenital bowel loss, or severe functional impairment. It is strongly associated with dependence on parenteral nutrition or intravenous fluids, recurrent dehydration, electrolyte imbalance, catheter-related bloodstream infection, kidney complications, and intestinal failure-associated liver disease.

For pharmaceutical and biotechnology stakeholders, the short bowel syndrome market is defined by orphan-disease economics, specialized prescribing, and measurable clinical endpoints such as reduced parenteral support volume, fewer infusion days, improved hydration, and intestinal adaptation. FDA- and EMA-approved teduglutide established GLP-2 analog therapy as a validated pathway for eligible adults and pediatric patients, while next-generation enteroendocrine, microbiome, and regenerative approaches are reshaping long-term SBS treatment strategies.

Transformative Shifts in the SBS Treatment Landscape

The SBS landscape is shifting from lifelong nutritional replacement toward targeted intestinal rehabilitation. Multidisciplinary care models now combine diet optimization, oral rehydration strategies, anti-motility therapy, acid suppression, micronutrient management, home parenteral nutrition, surgical reconstruction, and GLP-2-based pharmacotherapy to reduce dependence on parenteral support.

Innovation is also moving toward longer-acting peptides, pediatric-friendly formulations, real-world evidence generation, and earlier intervention after bowel resection. Commercial success increasingly depends on demonstrating durability, safety in chronic use, reduction in hospital utilization, lower catheter-related complication burden, and compatibility with established intestinal failure programs.

Cumulative Impact of Artificial Intelligence on SBS Innovation

Artificial intelligence is becoming increasingly relevant across SBS drug development and commercialization. AI-enabled literature mining, biomarker discovery, digital phenotyping, and trial feasibility modeling can help identify high-risk subgroups, optimize inclusion criteria, and accelerate recruitment in a rare disease where patient numbers are limited and care is concentrated in specialist centers.

In clinical and commercial settings, AI can support parenteral nutrition optimization, adverse event prediction, electronic health record screening, remote monitoring, and real-world evidence analytics. The highest-value use cases are those that improve patient monitoring while preserving clinician oversight, data privacy, interoperability, and regulatory-grade validation.

Key Regional Insights Across Global SBS Care

North America remains a leading SBS treatment region due to established home parenteral nutrition infrastructure, orphan-drug pathways, specialty pharmacy networks, payer experience with rare-disease therapies, and a high concentration of intestinal rehabilitation centers. Europe benefits from cross-border clinical expertise, national intestinal failure services, and EMA-recognized SBS therapies, although reimbursement timing, health technology assessment outcomes, and access to home parenteral nutrition vary by country.

Asia-Pacific is gaining relevance as Japan, China, Australia, South Korea, and India expand advanced gastroenterology, pediatric surgery, clinical nutrition, and tertiary hospital capabilities. Latin America shows growing need for SBS care in Mexico, Brazil, and other urban referral settings, but access is shaped by public-private reimbursement gaps and specialized nutrition support capacity. The Middle East, particularly Gulf health systems, is investing in specialty care and hospital infrastructure, while Africa faces a larger access barrier due to limited intestinal failure centers, uneven parenteral nutrition availability, infection-control challenges, and constrained reimbursement for orphan therapies.

Key Group Insights for SBS Market Access

Within the European Union, centralized regulatory pathways and national health technology assessments influence the adoption of GLP-2 analogs and home parenteral nutrition services, making country-level evidence packages essential for access. G7 markets typically offer stronger rare-disease infrastructure, specialist referral pathways, home-care services, and pharmacovigilance systems that support premium SBS therapies when they demonstrate clinically meaningful reductions in parenteral support.

ASEAN and BRICS countries represent long-term opportunities as tertiary hospitals expand gastrointestinal surgery, pediatric care, and clinical nutrition programs, although access remains uneven between major urban centers and broader public health systems. GCC markets are investing in advanced specialty care, international clinical standards, and hospital-based nutrition support, while NATO countries broadly benefit from resilient medical supply chains, established hospital procurement systems, and emergency preparedness frameworks relevant to parenteral nutrition, infusion supplies, and SBS therapy continuity.

Key Country Insights for SBS Market Prioritization

The United States leads SBS commercialization through orphan-drug incentives, specialist intestinal failure centers, home infusion networks, and specialty pharmacy distribution. Canada emphasizes evidence-based reimbursement and provincial access pathways, while Mexico and Brazil are building access through tertiary hospitals, gastroenterology referral centers, and private-sector specialty care. The United Kingdom, Germany, France, Italy, and Spain have strong gastroenterology and clinical nutrition expertise, but differ in reimbursement speed, regional budget controls, home parenteral nutrition organization, and health technology assessment requirements.

Russia's access environment is influenced by localized procurement and specialty-care concentration in major cities. China and India offer significant unmet clinical need but uneven access to home parenteral nutrition, rare-disease reimbursement, and specialized intestinal rehabilitation services outside leading tertiary hospitals. Japan, Australia, and South Korea provide mature specialist networks, high-quality clinical governance, and established pathways for high-evidence therapies that reduce parenteral support burden and improve long-term SBS management.

Actionable Recommendations for SBS Industry Leaders

Industry leaders should prioritize evidence packages that connect SBS therapies to reduced parenteral nutrition volume, fewer infusion days, improved fluid balance, lower catheter complication risk, reduced hospitalization burden, and quality-of-life improvement. Outcomes should be measured through registries, long-term extension studies, patient-reported outcomes, and real-world evidence from intestinal failure centers.

Stakeholders should also build integrated access strategies covering specialist education, nutrition-team partnerships, home-care coordination, pediatric transition support, adherence services, and payer-ready health economic evidence. In rare SBS populations, durable leadership will depend on trust, safety transparency, evidence continuity, and practical support across diagnosis, treatment initiation, long-term monitoring, and home-based care.

Research Methodology for SBS Market Analysis

This executive summary is based on a structured review of publicly available clinical, regulatory, and healthcare delivery evidence related to short bowel syndrome, intestinal failure, parenteral nutrition, GLP-2 analog therapy, pediatric and adult care pathways, and regional access dynamics. Sources considered include regulatory approvals, clinical guidelines, peer-reviewed literature, health technology assessment principles, and rare-disease care infrastructure indicators.

Insights were synthesized using a triangulated approach that compares therapeutic standards, reimbursement conditions, regional healthcare capacity, clinical endpoint relevance, and stakeholder needs. The analysis avoids unverified market sizing, market share, and forecasting claims, and emphasizes evidence-backed drivers that shape clinical adoption, access, and commercialization strategy.

Conclusion: Strategic Outlook for Short Bowel Syndrome

Short bowel syndrome is evolving from a replacement-care condition into a targeted intestinal rehabilitation market. The clinical goal is no longer limited to survival on parenteral nutrition; it increasingly includes intestinal adaptation, fewer complications, improved independence, better hydration, and sustainable long-term outcomes.

For pharmaceutical innovators, the most attractive opportunities are therapies and support models that reduce parenteral dependence, demonstrate durable benefit, and integrate seamlessly into specialist SBS care. Evidence quality, access planning, home-care coordination, and patient-centered implementation will define competitive advantage in this rare and highly specialized treatment landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Short Bowel Syndrome Market, by Treatment Type

  • 7.1. Nutritional Support
    • 7.1.1. Parenteral Nutrition
    • 7.1.2. Enteral Nutrition
  • 7.2. Pharmacological Treatment
    • 7.2.1. GLP-2 Analogues
    • 7.2.2. Growth Hormone Therapy
    • 7.2.3. Glutamine Therapy
    • 7.2.4. Antibiotics
  • 7.3. Surgical Treatment
    • 7.3.1. Intestinal Lengthening Procedures
    • 7.3.2. Intestinal Transplantation

8. Short Bowel Syndrome Market, by Route Of Administration

  • 8.1. Parenteral
    • 8.1.1. Intravenous
    • 8.1.2. Subcutaneous
  • 8.2. Oral

9. Short Bowel Syndrome Market, by Patient Age

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Short Bowel Syndrome Market, by Etiology

  • 10.1. Trauma
  • 10.2. Crohn's Disease
  • 10.3. Mesenteric Ischemia
  • 10.4. Radiation Enteritis
  • 10.5. Tumor Resection

11. Short Bowel Syndrome Market, by End Use

  • 11.1. Home Care Facilities
  • 11.2. Hospitals
  • 11.3. Specialty Clinics
  • 11.4. Ambulatory Surgical Centers
  • 11.5. Research Institutes

12. Short Bowel Syndrome Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Short Bowel Syndrome Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Short Bowel Syndrome Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Ardelyx, Inc.
  • 16.2. Emmaus Life Sciences, Inc.
  • 16.3. Hanmi Pharmaceutical Co., Ltd.
  • 16.4. Ironwood Pharmaceuticals, Inc.
  • 16.5. Merck & Co., Inc.
  • 16.6. NorthSea Therapeutics B.V.
  • 16.7. Nutrinia Ltd.
  • 16.8. OxThera AB
  • 16.9. Pfizer Inc.
  • 16.10. PhaseBio Pharmaceuticals, Inc.
  • 16.11. Sancilio & Company, Inc.
  • 16.12. Takeda Pharmaceutical Company Limited
  • 16.13. Theriva Biologics, Inc.
  • 16.14. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHORT BOWEL SYNDROME MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL SHORT BOWEL SYNDROME MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL SHORT BOWEL SYNDROME MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL SHORT BOWEL SYNDROME MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUTRITIONAL SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUTRITIONAL SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUTRITIONAL SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLP-2 ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GLP-2 ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLP-2 ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GROWTH HORMONE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GROWTH HORMONE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GROWTH HORMONE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLUTAMINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GLUTAMINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLUTAMINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTESTINAL LENGTHENING PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTESTINAL LENGTHENING PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTESTINAL LENGTHENING PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTESTINAL TRANSPLANTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTESTINAL TRANSPLANTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTESTINAL TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TRAUMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRAUMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRAUMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CROHN'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CROHN'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CROHN'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MESENTERIC ISCHEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MESENTERIC ISCHEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MESENTERIC ISCHEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RADIATION ENTERITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RADIATION ENTERITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RADIATION ENTERITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TUMOR RESECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TUMOR RESECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TUMOR RESECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOME CARE FACILITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOME CARE FACILITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOME CARE FACILITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 166. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 167. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 168. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 170. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 193. G7 SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 196. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 197. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 198. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 200. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 206. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 207. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 208. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 210. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 231. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 281. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 282. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 291. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 292. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 299. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 301. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 302. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 308. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 309. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 310. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 311. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 312. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 328. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 329. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 330. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 331. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 332. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 333. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 334. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 337. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 338. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 339. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 340. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 341. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 342. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 343. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 344. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 347. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 348. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 349. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 350. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 351. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 352. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 354. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 355. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2018-2032 (USD MILLION)

TABLE 3